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ABSTRACT
Objectives: We conducted a protocol-based cohort study to evaluate the outcomes of 
interval debulking surgery (IDS) followed by paclitaxel-based hyperthermic intraperitoneal 
chemotherapy (HIPEC) for the treatment of advanced-stage ovarian cancer.
Methods: From October 2015 to May 2018, 65 patients with stages IIIC–IV ovarian cancer were 
treated according to the study protocol. HIPEC was performed with paclitaxel (175 mg/m2) for 
90 minutes, only in cases of optimal cytoreduction.
Results: Of 65 patients, 40 (61.5%) patients underwent neoadjuvant chemotherapy (NAC), 34 
(52.3%) patients had a high tumor burden with a Fagotti score ≥8 at diagnostic laparoscopy, 
and 6 (9.2%) had definite stage IV metastasis and/or poor performance status before NAC. 
Twenty-seven (41.5%) patients underwent IDS followed by HIPEC. The mean duration of IDS 
with HIPEC was 543.8 (range, 277.0–915.0) minutes. Grade III/IV perioperative complications 
occurred in 7.4% (n=2)/3.7% (n=1) of patients and no cases of mortality were reported within 
30 days postoperatively. The median progression-free survival was 21.3 months, and the 
median overall survival was not reached for those who received HIPEC.
Conclusions: According to our study protocol, IDS followed by paclitaxel-based HIPEC as a 
first-line treatment appears to be feasible and safe for the treatment of advanced-stage ovarian 
cancer. Further evaluations of this procedure are required to assess its survival benefits.
Keywords: Ovarian Neoplasms; Hyperthermic Intraperitoneal Chemotherapy; Surgery; 
Paclitaxel; Drug Therapy
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INTRODUCTION
Cytoreductive surgery combined with platinum-based combination chemotherapy is the 
standard treatment for advanced-stage ovarian cancer [1]. However, approximately 80% 
of patients with advanced-stage disease experience recurrence and most die of the disease 
within 5 years of diagnosis [2]. To improve survival outcomes, the method of chemotherapy 
administration has been investigated.
Hyperthermic intraperitoneal chemotherapy (HIPEC) is a multi-modal approach that 
combines intraperitoneal chemotherapy and hyperthermia. It maintains the theoretical 
benefit of intraperitoneal chemotherapy and reduces most adverse events from catheter-
related problems with delivery of the chemotherapeutic agent at the end of surgery. In 
addition, hyperthermia is directly cytotoxic, increases the penetration of chemotherapy at the 
peritoneal surface, and increases the chemosensitivity of cancer cells [3].
In advanced-stage ovarian cancer, primary debulking surgery (PDS) often requires a long 
duration, massive transfusion (because of bleeding), and multiple bowel resections to 
achieve optimal cytoreduction. For such cases, the incorporation of HIPEC during surgery 
might contribute to a higher morbidity. Neoadjuvant chemotherapy (NAC) followed by 
interval debulking surgery (IDS) could be an alternative to reduce perioperative morbidity 
[4,5]. HIPEC after NAC is a feasible and relatively safe option, decreasing the tumor burden 
and the number of IDS procedures. Recently, a randomized, phase 3 trial showed that the 
addition of HIPEC to IDS improved progression-free survival (PFS) and overall survival (OS) 
compared to surgery alone [6].
However, there are some limitations regarding the addition of HIPEC to IDS, as follows: there 
is no consensus regarding the application of HIPEC to all patients, and there is an unresolved 
concern about whether the efficacy of HIPEC differs according to the response after NAC and 
the residual disease at IDS. Therefore, we designed a protocol for advanced-stage ovarian 
cancer and treated patients based on the response after NAC and the residual disease at IDS. 
This study aimed to evaluate the feasibility and safety of IDS followed by HIPEC as part of the 
first-line treatment in patients with stage III/IV ovarian cancer.
MATERIALS AND METHODS
We developed a protocol for the current study, and one gynecologic oncologist performed 
all procedures according to the study protocol. We recruited patients with advanced-stage 
ovarian cancer, consecutively, between October 2015 and May 2018. The incorporation 
of HIPEC after IDS was first introduced at Yonsei Cancer Hospital in October 2015. 
The eligibility criteria were as follows: 1) patients with histopathologically confirmed 
International Federation of Gynecology and Obstetrics stage III or IV ovarian, fallopian 
tube, and primary peritoneal carcinoma. In the cases of stage IV, distant metastases were 
supradiaphragmatic lymph node metastasis and/or parenchymal liver metastasis. Most 
patients achieved near-complete remission (no uptake on positron emission tomography-
computed tomography [CT], no gross lesions on chest CT) at the supradiaphragmatic lymph 
node after NAC. When the distant metastatic lesion remained, it was removed from the IDS; 
2) patients who underwent IDS following NAC; and 3) patients who received more than 1 
cycle of NAC before IDS.
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This study was reviewed and approved by the institutional review board (IRB) at Severance 
Hospital, Yonsei University Health System, Seoul, Korea (IRB number 4-2018-0518).
1. Advanced-stage ovarian cancer management protocol
The advanced-stage ovarian cancer management protocol used in our study is described 
in Fig. 1. All the patients, who were referred to one gynecologic oncologist for HIPEC, 
were thoroughly evaluated in order to determine the tumor burden of ovarian cancer. The 
diagnostic workup included esophagogastroduodenoscopy, colonoscopy, and CT of the 
chest, abdomen, and pelvis, with intravenous contrast agents. Positron-emission tomography 
CT was considered if extra-abdominal metastasis was suspected or difficult to detect by CT.
Our institution applied the following selection criteria for the use of NAC as the primary 
treatment strategy. NAC was performed when one of the following three criteria was met: 
1) high tumor dissemination was observed on initial imaging studies and was assumed 
to occur under the following conditions: a) multiple and unresectable extra-abdominal 
metastases; b) multiple liver parenchymal metastases or pulmonary metastases; and c) 
extensive small bowel/mesenteric root involvement, 2) patients had a poor performance 
status and high operative risk because of medical comorbidities, or 3) optimal debulking 
surgery (residual disease measuring 1 cm or less) was unsuitable because of a high tumor 
burden (Fagotti score ≥8). For diagnostic laparoscopy, the degree of tumor burden was 
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IDS without HIPEC (n=13)
Complete remission after NAC (n=4)
Excessive bleeding at IDS (n=3)
Suboptimal cytoreduction at IDS (n=1)
Poor performance status (n=4)
Patient’s refusal of HIPEC (n=1)
HTD at imaging findings
ASA ≥3 or ECOG ≥2
PDS (n=25)
Fagotti score <8
Yes No
Fagotti score ≥8
NAC (n=34)
IDS (n=40)
NAC (n=6)
HTD at imaging findings (n=5)
Poor performance status (n=1)
Diagnostic laparoscopy (n=59)
IDS+HIPEC (n=27)
Advanced ovarian cancer who received procedures according to 
study protocol between 2015 and 2018 (n=65)
Fig. 1. Flow diagram of the study population. 
ASA, American Society of Anesthesiologists; ECOG, Eastern Cooperative Oncology Group; HIPEC, hyperthermic intraperitoneal chemotherapy; HTD, high tumor 
dissemination; IDS, interval debulking surgery; NAC, neoadjuvant chemotherapy; PDS, primary debulking surgery.
determined with the peritoneal carcinomatosis index (PCI) described by Harmon and 
Sugarbaker [7] and the Fagotti score [8].
All patients, preferably, were recommended to receive 3 cycles of NAC, IDS followed by HIPEC, 
and 3 cycles of postoperative adjuvant chemotherapy (POAC). HIPEC was not incorporated in 
patients in whom complete remission was achieved after 3 cycles of NAC. After NAC, complete 
remission was determined by a combination of the response to chemotherapy and radiologic 
findings and by the absence of operative findings of gross visible tumors. Additionally, HIPEC 
was not performed in patients with excessive bleeding (estimated blood loss ≥4,000 mL) during 
surgery and in cases of patient refusal. For NAC and POAC, all patients received carboplatin 
(area under the curve of 5 to 6) and paclitaxel (175 mg/m2).
At the time of IDS, the degree of tumor burden was also determined with Harmon and 
Sugarbaker's PCI and the Fagotti score. All patients underwent surgery with the intent to 
achieve complete cytoreduction (no gross residual disease). Every patient underwent the same 
routine of procedures, beginning with complete omentectomy, hysterectomy, bilateral salpingo-
oophorectomy, and the removal of all macroscopically detectable lesions using surgical resection 
combined with electrofulguration, after peritonectomy techniques. If the rectosigmoid region 
was affected, it was resected ‘en bloc’ with digestive reconstruction by mechanical colorectal 
anastomosis. If the diaphragmatic region was affected, liver mobilization and diaphragmatic 
peritonectomy were performed. Pelvic and para-aortic lymphadenectomy was performed only for 
patients with gross nodal disease detected by preoperative imaging studies or operative findings.
HIPEC was performed immediately postoperatively. Of 27 HIPEC cases, 22 were performed using 
closed methods and 5 were performed using the open method. Paclitaxel was used at a dose of 175 
mg/m2, and chemotherapeutic agents were diluted in 3 L of 1.5% dextrose solution for peritoneal 
dialysis. Initially, 3 L of a heated perfusion solution was infused into the abdominal cavity at a rate 
of 800–1,000 mL/min through the inflow tube using the Belmont Hyperthermic Pump (Belmont 
Instrument Corporation, Billerica, MA, USA). Three intra-abdominal thermometers (1 positioned 
in the pelvis and 2 in the diaphragm area) were used to monitor the temperature inside the 
peritoneal cavity during the infusion, which remained constant between 42°C. The duration of 
the HIPEC procedure was 90 minutes, after which the perfusion solution was completely drained 
and bowel anastomosis was performed by the colorectal surgeon (MS Cho) if needed.
2. Endpoints and statistical analysis
The primary endpoint was PFS. The secondary endpoints included treatment morbidity and 
OS. The analysis was performed on an intention-to-treat basis. All patients who started the 
treatment were included in the analysis.
Data of patient demographic and clinical characteristics are summarized using standard 
descriptive statistics. Disease progression was defined according to the response evaluation 
criteria in solid tumors, version 1.1 or based on an increase from baseline in the cancer 
antigen (CA)-125 level, whichever one of those criteria was met first, as recommended by the 
Gynecologic Cancer Intergroup. OS was defined as the time from diagnosis until death due to 
any cause. PFS and OS curves were estimated using the Kaplan-Meier method. Perioperative 
complications were graded according to the Memorial Sloan-Kettering Cancer Center 
surgical secondary events grading system [9]. Major complications were defined as Memorial 
Sloan-Kettering Cancer Center (MSKCC) grade ≥III. Operative mortality was defined as 
death occurring within 30 days postoperatively (grade V). Other adverse events were graded 
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according to the National Cancer Institute Common Terminology Criteria for Adverse Events 
Version 3.0. The analyses were performed using SPSS (version 21.0; IBM Corp., Armonk, NY, 
USA). Statistical significance was assumed at p<0.05.
RESULTS
1. Patients' characteristics
During the study period, 65 women were treated by one gynecologic oncologist using the 
advanced-stage ovarian cancer management protocol. After excluding 25 patients treated 
with PDS, 40 patients were enrolled in the study. HIPEC was not performed in 13 of the 40 
patients for the following reasons: complete remission after NAC in 4 patients, excessive 
bleeding during the procedure in 3 patients (hepatic segmentectomy, iliac vein rupture, severe 
adhesions in pelvic cavity), suboptimal cytoreduction in 1 patient, poor performance status 
in 4 patients, and patient refusal in 1 patient. Twenty-seven patients underwent HIPEC, with 
a 175 mg/m2 paclitaxel infusion administered into the peritoneal cavity over 90 minutes at an 
inflow temperature of 42°C (Fig. 1). The demographic and baseline disease characteristics and 
surgical and treatment information are shown in Table 1. At baseline, the median patient age 
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Table 1. Patients' characteristics and surgical information (n=40)
Baseline characteristics Values
Median age (yr) 63 (43–77)
Comorbidity
Hypertension 12 (30.0)
Diabetes 5 (12.5)
Hypothyroidism 4 (10.0)
Other 4 (10.0)
Histologic type
Serous 37 (92.5)
Clear cell 2 (5.0)
Carcinosarcoma 1 (2.5)
FIGO stage
III 17 (42.5)
IV 23 (57.5)
ASA score
2 16 (40.0)
3 24 (60.0)
Median CA-125 level (U/mL) 1,691.7 (75.2–17,303.1)
Cycles of NAC 3 (1–4)
Fagotti score at diagnostic laparoscopy 10 (8–14)
Surgical procedure
Diaphragmatic peritonectomy 24 (60.0)
Splenectomy 10 (25.0)
Bowel resection 11 (27.5)
Pelvic and paraaortic lymph-node dissection 28 (70.0)
Residual disease (cm)
Not gross 17 (42.5)
≤0.5 20 (50.0)
≤1.0 3 (7.5)
>1.0 0 (0)
Mean operative time (min) 509.0 (129–915)
Blood transfusion during surgery 29 (72.5)
Median time interval between surgery and the start of 
adjuvant chemotherapy
21 (8–50)
Values are presented as median (range) or number of patients (%).
ASA, American Society of Anesthesiologists; CA, cancer antigen; FIGO, International Federation of Gynecology 
and Obstetrics; NAC, neoadjuvant chemotherapy.
was 63 (range, 43–77) years, 62.5% of the patients presented with comorbidities (hypertension, 
diabetes, hypothyroidism, etc.), and 57.5% of the patients had stage IV metastasis. Sixteen stage 
IV patients underwent IDS with HIPEC. Twelve patients had supradiaphragmatic lymph node 
metastasis, and 4 patients had parenchymal liver metastases. Eleven patients achieved near-
complete remission after NAC. The metastatic lesions remained in 5 patients after NAC and was 
removed from the IDS. The median CA-125 level was 1691.7 (range, 75.2–17,303.1) U/mL. Thirty-
seven (92.5%) patients had serous histology. The median number of NAC cycles was 3 (range, 
1–4). The median number of PCIs at diagnostic laparoscopy was 10 (range, 8–14). Twenty-four 
(60.0%) patients underwent diaphragmatic peritonectomy, 11 (27.5%) patients underwent 
bowel resection at IDS, and 28 (70%) patients underwent pelvic or paraaortic lymph-node 
dissection. In 14 patients (46.7%), no gross residual tumor was observed after IDS. The mean 
operative time was 509.0 (range, 129–915) minutes. Twenty-nine (72.5%) patients received 
blood transfusion during surgery. The median time interval between IDS and POAC initiation 
was 21 (range, 8–50) days. The surgical findings and postoperative outcomes of patients 
treated with HIPEC are shown in Table 2. The median value of PCI at IDS was 8 (range, 1–16), 
and 6 (22.2%) patients showed high tumor burden (Fagotti score ≥8). Two patients showed an 
estimated blood loss of 2–4 L and 4 patients received more than 5 units of blood transfusion. 
The mean operative time was 543.8 (range, 277–915) minutes. Five (18.5%) patients had major 
postoperative morbidity (restricted to grades III–V).
2. Safety and treatment administration
The median hospital stay was 12 (range, 3–131) days. No patients died within 30 days 
postoperatively (grade V events). Major postoperative morbidity (restricted to grades 
III–V) was encountered in 5 patients and resolved completely in 4 (Table 3). Among these, 
2 patients needed secondary surgical revision. One patient underwent total mastectomy 
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Table 2. Surgical findings and postoperative outcomes of HIPEC (n=27)
Variables Values
PCI (median and range) 8 (1–16)
Tumor burden*
Low (PIV ≤2) 7 (25.9)
Intermediate (PIV 4–6) 14 (51.9)
High (PIV ≥8) 6 (22.2)
Estimated blood loss (L)
≤1 15 (55.6)
1–2 10 (37.0)
2–4 2 (7.4)
Intraoperative blood transfusion (units)
None 8 (29.6)
1–2 10 (37.0)
3–4 5 (18.6)
≥5 4 (14.8)
Operative time (min) 543.8 (277.0–915.0)
Complication grade†
0 8 (29.6)
1 5 (18.6)
2 9 (33.3)
3 4 (14.8)
4 1 (3.7)
5 0 (0)
Length of hospitalization (days) 18.7 (5.0–131.0)
Values are presented as median (range) or number of patients (%).
HIPEC, hyperthermic intraperitoneal chemotherapy; PCI, peritoneal cancer index; PIV, predictive index value
*According to Fagotti et al. [8]; †According to the Memorial Sloan-Kettering Cancer Center surgical secondary 
events grading system [9].
with axillary lymph node dissection because of breast cancer at the time of IDS with HIPEC 
and underwent emergency surgery for postoperative breast hematoma. The other patient 
underwent prompt surgical intervention 2 weeks postoperatively because of sudden bleeding 
in the mesenteric vessel. This patient had deep venous thrombosis in the right infra-
popliteal vein due to carcinomatosis at the time of diagnosis, and anticoagulation therapy 
was continued before and after IDS. The sequela of hypoxic brain damage prevented the 
administration of POAC.
The median time interval to POAC after IDS was 20 (range, 8–50) days; POAC was 
initiated for 14 (46.7%) patients after 20 days. This delay was mostly due to postoperative 
complications of radical surgery. The patient with the greatest delay was reintubated because 
of severe pulmonary edema and was then readmitted to the intensive care unit.
3. Survival
After a median follow-up of 14.5 months, 42 (64.6%) patients were alive and disease-free, 21 
(32.3%) patients were alive but had a relapse, and 2 (3.1%) patient died of disease-related causes.
The median PFS was 19.7 months and the median OS was not reached for those who received 
NAC (Fig. 2). The median PFS was 21.3 months, and the median OS was not reached for 
those who received HIPEC (Fig. 3). Considering all 65 patients with advanced-stage disease, 
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Table 3. Postoperative grade III/IV complications according to the Memorial Sloan-Kettering Cancer Center surgical secondary events grading system from days 0 to 30
Case No. Previous 
surgery
Surgical procedure Type of 
complication
Postoperative 
day
Reintervention Return 
to ICU
Sequelae
1 None Conventional surgery*/VATS/HIPEC/total 
mastectomy with axillary lymph node dissection
Breast hematoma 1 Yes 
(reoperation)
Yes No
2 Appendectomy Conventional surgery/large bowel resection/
splenectomy/diaphragmatic peritonectomy
Pulmonary edema, 
pleural effusion
10 Yes Yes No
3 None Conventional surgery/splenectomy/liver resection Pleural effusion 7 Yes No No
4 None Conventional surgery/large bowel resection/
diaphragmatic peritonectomy/HIPEC
Pneumonia 3 Yes Yes No
5 None Conventional surgery/large bowel resection/
splenectomy/HIPEC
Hemoperitoneum 16 Yes 
(reoperation)
Yes Yes  
(hypoxic brain damage)
HIPEC, hyperthermic intraperitoneal chemotherapy; ICU, intensive care unit; VATS, video-assisted thoracoscopic surgery.
*Conventional surgery included hysterectomy, bilateral oophorectomy and omentectomy, pelvic/para-aortic lymph node dissection, and appendectomy.
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Fig. 2. Kaplan-Meier curves of PFS (A) and OS (B) in NAC. 
NAC, neoadjuvant chemotherapy; OS, overall survival; PFS, progression-free survival.
including those who underwent PDS, the median PFS was 21.3 months, and the median OS 
was not reached (Supplementary Fig. 1).
DISCUSSION
Our study showed the feasibility and acceptable toxicity of adding HIPEC to the standard 
first-line treatment for patients with advanced-stage ovarian cancer. Paclitaxel-based HIPEC 
resulted in major postoperative complications (MSKCC grade ≥III) in 5/18 (27.8%) patients, 
and 2 (11.1%) of them required prompt repeat surgery. In 2 cases, reoperation was performed 
after IDS, but this was considered to not be directly related to HIPEC.
As a triage strategy for the response after NAC and residual disease on IDS in patients with 
advanced-stage ovarian cancer, IDS followed by HIPEC as a first-line treatment according 
to our institution's management protocol seems to have had little effect on the safety and 
postoperative complications. In patients with a good response after NAC, tumor burden and 
extensive IDS procedures are reduced. Therefore, NAC can reduce the adverse effects and 
postoperative complications of IDS followed by HIPEC. In patients with poor response to 
NAC, the effect of HIPEC can alter responsiveness to platinum-based chemotherapy. Hettinga 
et al. [10] investigated the mechanism underlying the interaction between the effects of 
hyperthermia and chemotherapy cytotoxicity in cisplatin-sensitive and cisplatin-resistant 
cell lines. At a temperature of 43°C, the intracellular accumulation of cisplatin was shown to 
be higher in resistant lines than in sensitive lines [10]. Another possible explanation is that 
hyperthermia leads to the activation of heat-shock proteins, which, in turn, modify multiple 
cellular functions through their interference with protein folding. It is known that neoplastic 
cells express higher amounts of heat-shock proteins, therefore, becoming more susceptible 
to the effect of increased temperature [11].
Several studies have shown that the combination of IDS with HIPEC for the treatment of 
ovarian cancer is feasible and reasonably well-tolerated [12-14]. Recently, a phase 3 clinical 
trial demonstrated that performing IDS followed by HIPEC improved survival outcomes 
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Fig. 3. Kaplan-Meier curves of PFS (A) and OS (B) in HIPEC. 
HIPEC, hyperthermic intraperitoneal chemotherapy; OS, overall survival; PFS, progression-free survival.
among patients who had received NAC for stage III epithelial ovarian cancer. The patients 
who had, at least, stable disease after 3 cycles of NAC were randomly assigned to undergo 
IDS with or without the incorporation of HIPEC with cisplatin. The incorporation of HIPEC 
resulted in a longer recurrence-free survival and OS compared to IDS alone and did not result 
in higher rates of postoperative complications.
Specific drug toxicity is frequently associated with surgical toxicity in HIPEC; however, 
paclitaxel did not appear to cause any major toxicity compared to other drugs used in 
HIPEC. Paclitaxel has a high molecular weight and is highly metabolized by the liver; thus, 
it is associated with very low rates of systemic toxicity and is less likely to penetrate the 
peritoneum. Cascales-Campos et al. [15] reported that patients with stage III/IV ovarian 
cancer treated with IDS and HIPEC after NAC using paclitaxel had better survival outcomes 
than those treated with IDS without HIPEC; the results of disease-free survival (DFS) were 
significantly better in the group of patients treated with HIPEC. Bae et al. [16] demonstrated, 
in patients with advanced-stage ovarian cancer, a significant improvement in survival for 
the group treated with HIPEC using paclitaxel or carboplatin; in this study, DFS rates at 
3 years were 56.3% in the HIPEC group and 16.7% in the control group (without HIPEC). 
Furthermore, the 5-year survival rates were 84.6% in the paclitaxel group, 63% in the 
carboplatin group, and 32.8% in the control group. HIPEC using paclitaxel, which was 
employed in this study, has been approved in South Korea as a new medical technology, 
and the Health Insurance Review & Assessment Service has approved paclitaxel-based 
HIPEC therapy since 2015 in Yonsei Cancer Hospital. Compared to paclitaxel, carboplatin in 
HIPEC has demonstrated no synergism with heat [17], and docetaxel in HIPEC occasionally 
exhibits greater activity and enhanced toxicity [18]. Cisplatin is commonly used in many 
HIPEC protocols at variable doses for the treatment of advanced-stage ovarian cancer [19-21]. 
Nephrotoxicity and permanent renal dysfunction rarely occur in HIPEC with cisplatin [22]. 
In addition, Zanon et al. [23] reported a 6% incidence of nephrotoxicity in 30 patients with 
ovarian cancer using cisplatin with HIPEC.
Our study had some limitations. First, as a protocol-based pilot study, the number of patients 
analyzed was limited. In addition, the median survival was not reached, making the short 
follow-up period another limitation of the study.
We believe that incorporation of HIPEC in IDS will be not beneficial for all ovarian cancer 
patients. In this study, we applied HIPEC on the basis of the study protocol. Patients with 
complete remission after NAC were considered good responders, and some patients had 
no gross residual tumor without surgery. We performed laparoscopy without HIPEC for 
those group and initiated adjuvant chemotherapy immediately postoperatively. It might 
be preferable to administer chemotherapy without interruption from debulking surgery. 
However, some patients who were considered poor responders showed stable disease 
or progression of disease even after NAC. Second-line chemotherapy without IDS is 
recommended for poor responder. When applying IDS in poor responders, very aggressive 
surgery is required and optimal cytoreduction is difficult to achieve because of the tumor 
burden. We did not administer HIPEC to patients with unsuitable operative findings 
(suboptimal cytoreduction, excessive bleeding) and a poor performance status. Therefore, we 
applied IDS followed by HIPEC in a small population in which partial remission occurs after 
NAC and optimal debulking through IDS is achieved. These subgroups should be considered 
as the inclusion criteria for future clinical trials to determine the true benefit of IDS with 
HIPEC for ovarian cancer.
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In conclusion, our results show that the incorporation of IDS followed by HIPEC according 
to our institution's management protocol seems to be feasible and safe for the treatment of 
ovarian cancer patients. Further evaluations of this protocol are required to assess its survival 
benefits. Additional larger trials are needed to determine if IDS with HIPEC has survival 
benefits as first-line treatment. A multicenter prospective study on the addition of HIPEC to IDS 
(KGOG 3042) is underway and its results could clarify the role of HIPEC in first-line treatment.
SUPPLEMENTARY MATERIAL
Supplementary Fig. 1
Kaplan-Meier curves of PFS (A) and OS (B) in all patients.
Click here to view
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